Cargando…
Advances of Zebrafish in Neurodegenerative Disease: From Models to Drug Discovery
Neurodegenerative disease (NDD), including Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis, are characterized by the progressive loss of neurons which leads to the decline of motor and/or cognitive function. Currently, the prevalence of NDD is rapidly increasing in the ag...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8317260/ https://www.ncbi.nlm.nih.gov/pubmed/34335276 http://dx.doi.org/10.3389/fphar.2021.713963 |
_version_ | 1783730036960919552 |
---|---|
author | Wang, Xiaobo Zhang, Jin-Bao He, Kai-Jie Wang, Fen Liu, Chun-Feng |
author_facet | Wang, Xiaobo Zhang, Jin-Bao He, Kai-Jie Wang, Fen Liu, Chun-Feng |
author_sort | Wang, Xiaobo |
collection | PubMed |
description | Neurodegenerative disease (NDD), including Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis, are characterized by the progressive loss of neurons which leads to the decline of motor and/or cognitive function. Currently, the prevalence of NDD is rapidly increasing in the aging population. However, valid drugs or treatment for NDD are still lacking. The clinical heterogeneity and complex pathogenesis of NDD pose a great challenge for the development of disease-modifying therapies. Numerous animal models have been generated to mimic the pathological conditions of these diseases for drug discovery. Among them, zebrafish (Danio rerio) models are progressively emerging and becoming a powerful tool for in vivo study of NDD. Extensive use of zebrafish in pharmacology research or drug screening is due to the high conserved evolution and 87% homology to humans. In this review, we summarize the zebrafish models used in NDD studies, and highlight the recent findings on pharmacological targets for NDD treatment. As high-throughput platforms in zebrafish research have rapidly developed in recent years, we also discuss the application prospects of these new technologies in future NDD research. |
format | Online Article Text |
id | pubmed-8317260 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-83172602021-07-29 Advances of Zebrafish in Neurodegenerative Disease: From Models to Drug Discovery Wang, Xiaobo Zhang, Jin-Bao He, Kai-Jie Wang, Fen Liu, Chun-Feng Front Pharmacol Pharmacology Neurodegenerative disease (NDD), including Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis, are characterized by the progressive loss of neurons which leads to the decline of motor and/or cognitive function. Currently, the prevalence of NDD is rapidly increasing in the aging population. However, valid drugs or treatment for NDD are still lacking. The clinical heterogeneity and complex pathogenesis of NDD pose a great challenge for the development of disease-modifying therapies. Numerous animal models have been generated to mimic the pathological conditions of these diseases for drug discovery. Among them, zebrafish (Danio rerio) models are progressively emerging and becoming a powerful tool for in vivo study of NDD. Extensive use of zebrafish in pharmacology research or drug screening is due to the high conserved evolution and 87% homology to humans. In this review, we summarize the zebrafish models used in NDD studies, and highlight the recent findings on pharmacological targets for NDD treatment. As high-throughput platforms in zebrafish research have rapidly developed in recent years, we also discuss the application prospects of these new technologies in future NDD research. Frontiers Media S.A. 2021-07-14 /pmc/articles/PMC8317260/ /pubmed/34335276 http://dx.doi.org/10.3389/fphar.2021.713963 Text en Copyright © 2021 Wang, Zhang, He, Wang and Liu. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Wang, Xiaobo Zhang, Jin-Bao He, Kai-Jie Wang, Fen Liu, Chun-Feng Advances of Zebrafish in Neurodegenerative Disease: From Models to Drug Discovery |
title | Advances of Zebrafish in Neurodegenerative Disease: From Models to Drug Discovery |
title_full | Advances of Zebrafish in Neurodegenerative Disease: From Models to Drug Discovery |
title_fullStr | Advances of Zebrafish in Neurodegenerative Disease: From Models to Drug Discovery |
title_full_unstemmed | Advances of Zebrafish in Neurodegenerative Disease: From Models to Drug Discovery |
title_short | Advances of Zebrafish in Neurodegenerative Disease: From Models to Drug Discovery |
title_sort | advances of zebrafish in neurodegenerative disease: from models to drug discovery |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8317260/ https://www.ncbi.nlm.nih.gov/pubmed/34335276 http://dx.doi.org/10.3389/fphar.2021.713963 |
work_keys_str_mv | AT wangxiaobo advancesofzebrafishinneurodegenerativediseasefrommodelstodrugdiscovery AT zhangjinbao advancesofzebrafishinneurodegenerativediseasefrommodelstodrugdiscovery AT hekaijie advancesofzebrafishinneurodegenerativediseasefrommodelstodrugdiscovery AT wangfen advancesofzebrafishinneurodegenerativediseasefrommodelstodrugdiscovery AT liuchunfeng advancesofzebrafishinneurodegenerativediseasefrommodelstodrugdiscovery |